Release and bioactivity of PACA nanoparticles containing D-Lys6-GnRH for brushtail possum fertility control

Efficient Cytotoxicity of Recombinant Azurin in Escherichia coli Nissle 1917-Derived Minicells against Colon Cancer Cells

Compared to chemical drugs, therapeutic proteins exhibit higher specificity and activity and are generally well-tolerated by the human body. However, the limitations, such as poor stability both in vivo and in vitro as well as difficulties in penetrating cell membranes, hinder their widespread application. To overcome the challenges, a highly efficient protocol was developed and implemented for the recombinant expression of the therapeutic protein azurin and secretion into minicells derived from probiotic Escherichia coli Nissle 1917. The novel coupled production with a delivery system of therapeutic proteins based on minicells was obtained through purification to enhance protein activity, circulation characteristics, and targeting specificity. This protein drug carrier integrates the production of carrier materials and the loading of expression proteins. The drug carrier also protects the encapsulated polypeptide drugs from enzymatic or gastric acid degradation until they are released. Escherichia coli Nissle 1917-derived minicells have natural targeting to colon cancer cells, low toxicity, and can accumulate for a long time after penetrating tumor tissue. This self-produced protein drug delivery system simplified the process of protein preparation, and its inhibitory effect on different types of colon cancer cells was verified by CCK-8 cytotoxicity assay, cancer cell invasion, and migration assay. This work provided a simple method to prepare minicell drug delivery systems for protein drug production and a novel approach for the transport of recombinant protein drugs.

A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles

Starting in the late 1970s, the pioneering work of Patrick Couvreur gave birth to the first biodegradable nanoparticles composed of a biodegradable synthetic polymer. These nanoparticles, made of poly(alkylcyanoacrylate) (PACA), were the first synthetic polymer-based nanoparticulate drug carriers undergoing a phase III clinical trial so far. Analyzing the journey from the birth of PACA nanoparticles to their clinical evaluation, this paper highlights their remarkable adaptability to bypass various drug delivery challenges found on the way. At present, PACA nanoparticles include a wide range of nanoparticles that can associate drugs of different chemical nature and can be administered in vivo by different routes. The most recent technologies giving the nanoparticles customised functions could also be implemented on this family of nanoparticles. Through different examples, this paper discusses the seminal role of the PACA nanoparticles' family in the development of nanomedicines.

Nano-based smart pesticide formulations: Emerging opportunities for agriculture

The incorporation of nanotechnology as a means for nanopesticides is in the early stage of development. The main idea behind this incorporation is to lower the indiscriminate use of conventional pesticides to be in line with safe environmental applications. Nanoencapsulated pesticides can provide controlled release kinetics, while efficiently enhancing permeability, stability, and solubility. Nanoencapsulation can enhance the pest-control efficiency over extended durations by preventing the premature degradation of active ingredients (AIs) under harsh environmental conditions. This review is thus organized to critically assess the significant role of nanotechnology for encapsulation of AIs for pesticides. The smart delivery of pesticides is essential to reduce the dosage of AIs with enhanced efficacy and to overcome pesticide loss (e.g., due to leaching and evaporation). The future trends of pesticide nanoformulations including nanomaterials as AIs and nanoemulsions of biopesticides are also explored. This review should thus offer a valuable guide for establishing regulatory frameworks related to field applications of these nano-based pesticides in the near future.

Nanoencapsulation of phase change materials for advanced thermal energy storage systems

Phase change materials (PCMs) allow the storage of large amounts of latent heat during phase transition. They have the potential to both increase the efficiency of renewable energies such as solar power through storage of excess energy, which can be used at times of peak demand; and to reduce overall energy demand through passive thermal regulation. 198.3 million tons of oil equivalent were used in the EU in 2013 for heating. However, bulk PCMs are not suitable for use without prior encapsulation. Encapsulation in a shell material provides benefits such as protection of the PCM from the external environment and increased specific surface area to improve heat transfer. This review highlights techniques for the encapsulation of both organic and inorganic PCMs, paying particular attention to nanoencapsulation (capsules with sizes <1 μm). We also provide insight on future research, which should focus on (i) the development of multifunctional shell materials to improve lifespan and thermal properties and (ii) advanced mass manufacturing techniques for the economically viable production of PCM capsules, making it possible to utilize waste heat in intelligent passive thermal regulation systems, employing controlled, "on demand" energy release/uptake.

Lipid-based nanocarriers for oral peptide delivery

This article is aimed to overview the lipid-based nanostructures designed so far for the oral administration of peptides and proteins, and to analyze the influence of their composition and physicochemical (particle size, zeta potential) and pharmaceutical (drug loading and release) properties, on their interaction with the gastro-intestinal environment, and the subsequent PK/PD profile of the associated drugs. The ultimate goal has been to highlight and comparatively analyze the key factors that may be determinant of the success of these nanocarriers for oral peptide delivery. The article ends with some prospects on the challenges to be addressed for the intended commercial success of these delivery vehicles.

A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives

In the modern world, a number of therapeutic proteins such as vaccines, antigens, and hormones are being developed utilizing different sophisticated biotechnological techniques like recombinant DNA technology and protein purification. However, the major glitches in the optimal utilization of therapeutic proteins and peptides by the oral route are their extensive hepatic first-pass metabolism, degradation in the gastrointestinal tract (presence of enzymes and pH-dependent factors), large molecular size and poor permeation. These problems can be overcome by adopting techniques such as chemical transformation of protein structures, enzyme inhibitors, mucoadhesive polymers and permeation enhancers. Being invasive, parenteral route is inconvenient for the administration of protein and peptides, several research endeavors have been undertaken to formulate a better delivery system for proteins and peptides with major emphasis on non-invasive routes such as oral, transdermal, vaginal, rectal, pulmonary and intrauterine. This review article emphasizes on the recent advancements made in the delivery of protein and peptides by a non-invasive (peroral) route into the body.

Molecular characterization of kisspeptin gene and effect of nano-encapsulted kisspeptin-10 on reproductive maturation in Catla catla

Kisspeptin, a member of the RF-amide-related peptide family, has emerged recently as an essential gatekeeper of various reproductive processes via its ability to activate kisspeptin receptors at puberty. In this study, the kiss1 gene and its receptor kiss1rb were cloned and characterized from the brain of Catla catla. Further, the effects of kissppetin-10 (K-10) and chitosan-encapsulated K-10 nanoparticles (CK-10) on gene expression were assessed. The full-length complementary DNA sequence of kiss1 is 754 bp with an open reading frame of 351 bp that encodes a putative protein of 116 amino acids. The kiss1rb complementary DNA is 1,280 bp long and contains a 5'-untranslated region of 30 bp, 3'-untranslated region of 149 bp, and an open reading frame (open reading frame) of 1,101 bp. The expression patterns of kiss1 and kiss1rb messenger RNA (mRNA) in basal tissues revealed that they are mainly expressed in the brain, pituitary gland, and gonads. CK-10 nanoparticles with a particle size of 125 nm and a zeta potential of 36.45 mV were synthesized and compared with K-10. Chitosan nanoparticles showed 60% entrapment efficiency for K-10. The mRNA expression of reproductive genes (GnRH, LH, and FSH) in fish injected with K-10 declined after 6 h, whereas those injected with CK-10 showed controlled and a sustained surge of mRNA expression of these genes with a peak at 12 h. Histologic examination of ovaries indicated a pronounced effect of CK-10 on maturation and gonadal development. The study reports that this sustained release delivery system will help in increasing the half-life of K-10 and other therapeutic protein drugs in the biological system. Besides, the nanoformulation developed in the present study may be useful for developing therapies against various reproductive dysfunctions in vertebrates.